Oncogenic osteomalacia due to phosphaturic mesenchymal tumour in the upper thoracic spine.
Bhavuk GargNishank MehtaArchit GoyalRajesh KhadgawatPublished in: BMJ case reports (2020)
Oncogenic osteomalacia (OO) is an uncommon paraneoplastic syndrome occurring due to the presence of a tumour that oversecretes fibroblast growth factor-23, which impairs renal phosphate handling. In most cases, the tumour is a morphologically distinct entity called 'phosphaturic mesenchymal tumour' (PMT). Spinal tumours causing OO are exceedingly rare. A 55-year-old man presented with multiple bone pain and proximal muscle weakness in the lower limbs. The constellation of biochemical findings (hypophosphataemia, normocalcaemia, increased alkaline phosphatase, low-normal serum vitamin D and hyperphosphaturia) with radiographical rarefaction of the skeleton and pseudofractures led us to consider OO as a possibility. Functional imaging (68Ga DOTA-NOC positron emission tomography/CT scan) localised the tumour to the D2 vertebra. Complete surgical resection led to resolution of symptoms, improved ambulatory status, normalisation of biochemical parameters and healing of pseudofractures. PMT should be considered in the differential diagnosis of hypophosphataemic osteomalacia with hyperphosphaturia. Tumour localisation with functional imaging and complete surgical resection produces satisfactory outcome.
Keyphrases
- positron emission tomography
- computed tomography
- pet ct
- stem cells
- high resolution
- spinal cord
- pet imaging
- transcription factor
- skeletal muscle
- magnetic resonance imaging
- pain management
- spinal cord injury
- neuropathic pain
- photodynamic therapy
- dual energy
- contrast enhanced
- postmenopausal women
- sleep quality
- bone regeneration